CN111333687A - Method for extracting franocidine sulfate from neomycin sulfate - Google Patents
Method for extracting franocidine sulfate from neomycin sulfate Download PDFInfo
- Publication number
- CN111333687A CN111333687A CN202010165669.1A CN202010165669A CN111333687A CN 111333687 A CN111333687 A CN 111333687A CN 202010165669 A CN202010165669 A CN 202010165669A CN 111333687 A CN111333687 A CN 111333687A
- Authority
- CN
- China
- Prior art keywords
- sulfate
- neomycin
- franocidine
- extracting
- neomycin sulfate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
- C07H1/06—Separation; Purification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/22—Cyclohexane rings, substituted by nitrogen atoms
- C07H15/222—Cyclohexane rings substituted by at least two nitrogen atoms
- C07H15/226—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
- C07H15/228—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
- C07H15/232—Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with at least three saccharide radicals in the molecule, e.g. lividomycin, neomycin, paromomycin
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a method for extracting franocidine sulfate from neomycin sulfate, which comprises the following steps: s1, dissolving the concentrated neomycin sulfate raw powder with purified water to obtain neomycin sulfate concentrated solution, and adding chromatographic resin for adsorption; s2, washing the saturated chromatographic resin in the S1 by ammonia water; s3, eluting the chromatography resin treated by the S2 with ammonia water to obtain an eluent; s4, concentrating the eluent by a thin film evaporator to obtain a concentrated solution; s5, carrying out a salt conversion operation on sulfuric acid in the concentrated solution; s6, adding activated carbon into the salt-converted concentrated solution for decolorization and filter pressing to obtain a decolorized solution; s7, spray drying the decolored solution at the temperature of 135 ℃ to obtain a finished product of the Francidine sulfate. The invention adopts spray drying to replace crystallization operation, uses no organic solvent, ensures that the formed finished product of the Franciseline sulfate has no organic solvent residue, improves the yield of the finished product and the product quality, has low production cost, and simultaneously has no organic matter after the waste liquid is discharged.
Description
Technical Field
The invention relates to the technical field of medicine extraction, in particular to a method for extracting franocidine sulfate from neomycin sulfate.
Background
The invented franocidine sulfate (neomycin sulfate B) is an aminoglycoside antibiotic separated and extracted from neomycin sulfate finished product raw powder, and possesses good antibacterial action for staphylococcus aureus and corynebacterium, and also has good action for enterobacter of escherichia coli, klebsiella and proteus, etc. it overcomes the side effect of neomycin sulfate, and can be made into injection, powder preparation and ointment preparation.
Francidine sulfate is commonly prepared by separating from neomycin sulfate product raw powder. The neomycin sulfate consists of neomycin sulfate B, neomycin sulfate C and impurities, wherein the neomycin sulfate B and the neomycin sulfate C are stereoisomers of each other, the content of the neomycin sulfate B is 75-82%, the content of the neomycin sulfate C is 15-18%, and the other parts are neomycin amine and other impurities. Neomycin sulfate B has 60 times more antibacterial activity than neomycin sulfate C, and in contrast neomycin sulfate C has almost no antibacterial activity, but 300 times more toxicity than neomycin sulfate B. Reducing the content of neomycin C sulfate to be less than 3.0 percent, obtaining the franciclovir sulfate (other impurities are reduced in the process), wherein the activity of the franciclovir sulfate is 1.3 times of that of neomycin sulfate, but the toxicity of the franciclovir sulfate is only equal to 1/60 of the neomycin sulfate. The method generally comprises the procedures of fermentation, filtration, decoloration, adsorption, desorption, concentration, decoloration, crystallization and drying, namely, raw powder of a neomycin sulfate finished product is adsorbed by resin and then is desorbed by eluent to obtain desorption solution, and the desorption solution is concentrated, decolored, crystallized in methanol and dried to obtain the franocidine sulfate.
However, the preparation method of the franocidin sulfate has a plurality of defects, the production process is complex, special detection equipment is required, and the detection method is complex. For example, the resin used has a small adsorption amount, a low analytical yield, a large consumption of raw materials, and a high cost. Methanol is used as a solvent for precipitation in the crystallization process, so that the cost is high, the environment is polluted by the emission of the methanol, and the residual content of the organic solvent in the prepared product is high.
Disclosure of Invention
Aiming at the defects of the prior art, the invention provides a method for extracting franocidine sulfate from neomycin sulfate, which has the defects of low analytic yield, large raw material consumption, high cost, high solvent cost in the crystallization process, reduction of the purity of a crystallization product and secondary pollution to the environment after discharge.
In order to achieve the purpose, the invention is realized by the following technical scheme:
a method for extracting franocidine sulfate from neomycin sulfate comprises the following steps:
s1, dissolving the concentrated neomycin sulfate raw powder with purified water with the weight 20-40 times that of the raw powder to obtain neomycin sulfate concentrated solution, adding chromatographic resin, and adsorbing for 3-4 hours under the stirring condition until the chromatographic resin is saturated;
s2, washing the saturated chromatographic resin in the S1 by 0.1-0.5mol/L ammonia water;
s3, eluting the chromatography resin treated by the S2 by using 1.1-1.5mol/L ammonia water to obtain eluent;
s4, concentrating the eluent by a thin film evaporator until the concentration of the eluent is 120000-200000u/ml to obtain a concentrated solution;
s5, adding sulfuric acid into the concentrated solution to carry out salt conversion operation;
s6, adding activated carbon into the salt-converted concentrated solution for decolorization and filter pressing to obtain a decolorized solution;
s7, spray drying the decolored solution at the temperature of 135 ℃ to obtain a finished product of the Francidine sulfate.
Further, the mass-to-volume ratio of the neomycin sulfate raw powder to the chromatography resin in the S1 is 1: 5.
Furthermore, the chromatographic resin in the S1 is selected from one of HZ001, HZ201, LK20, LKC158, HZ201, HZ3B and HPC 3500.
Further, the flow rate of ammonia water washing in the S2 and S3 is 0.1-0.2 times of the volume of the chromatography resin per hour.
Further, the amount of the ammonia water in the S2 is 3-4 times of the volume of the chromatography resin.
Further, the elution of ammonia water in S3 is stopped until the eluent is not turbid when titrated with 5% phosphotungstic acid.
Further, the conditions for concentration in S4: the steam temperature is 40-50 ℃, and the vacuum degree is more than or equal to 0.085 MPa.
Further, the concentration of sulfuric acid in the salt transferring operation in S5 is 6 to 9mol/L, and the pH of the salt transferring operation is controlled to 6.0 to 7.0.
Further, the finished product of the franocidine sulfate in S7 has the following medicine quality parameters: the potency is 650-654u/mg, the content of neomycin C is 1.6-2.0%.
Has the advantages that:
1. the method takes the neomycin sulfate raw powder as the raw material, adopts the chromatographic resin for selective adsorption, has good separation effect, and carries out washing and analysis through the ammonia water concentration with concentration gradient so as to reduce the dosage of the ammonia water eluent and facilitate the subsequent concentration and crystallization operation.
2. The invention adopts ammonia water for washing, and then uses phosphotungstic acid for titration detection, thereby reducing the complexity of the process and simplifying the operation.
3. The invention adopts spray drying to replace crystallization operation without using organic solvent, so that the formed finished product of the Franciseline sulfate has no organic solvent residue, the yield of the finished product and the quality of the product are improved, the production cost is low, and simultaneously, no organic matter exists after the waste liquid is discharged, and the secondary pollution of the discharge to the environment can be reduced.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1:
the embodiment of the invention provides a method for extracting franocidine sulfate from neomycin sulfate, which comprises the following steps:
s1, dissolving the concentrated neomycin sulfate raw powder with purified water with the weight 20-40 times that of the raw powder to obtain neomycin sulfate concentrated solution, adding a chromatographic resin with the model of HZ001, and adsorbing for 3-4 hours under the stirring condition, wherein the mass-to-volume ratio of the neomycin sulfate raw powder to the chromatographic resin is 1:5 until the chromatographic resin is saturated.
S2, washing the saturated chromatographic resin in the S1 by 0.1mol/L ammonia water, controlling the flow rate of the ammonia water to be 0.1 time of the volume of the chromatographic resin per hour (the flow rate of the ammonia water used in the S3 is the same), and washing the neomycin C and other impurities until the washing amount of the ammonia water is 3-4 times of the volume of the chromatographic resin.
S3, continuing to elute the neomycin sulfate B from the chromatography resin treated by the S2 by using 1.1mol/L ammonia water, starting to receive the eluent to an eluent receiving tank, and stopping eluting when the eluent is not turbid after being titrated by 5% phosphotungstic acid to obtain the eluent.
S4, concentrating the eluent by a thin film evaporator until the concentration of the eluent is 120000-180000u/ml, and obtaining a concentrated solution, wherein the using conditions of the thin film evaporator are as follows: the steam temperature is 40-50 ℃, the vacuum degree is more than or equal to 0.085MPa, and the application conditions of the following embodiments are the same.
S5, adding 6mol/L sulfuric acid into the concentrated solution to adjust the pH value of the concentrated solution to 7, and carrying out the salt conversion operation.
S6, adding activated carbon into the concentrated solution of the reverse salt according to 0.05 kg/billion unit for decolorization, and performing filter pressing to obtain a decolorized solution.
S7, spray drying the decolored solution at the temperature of 135 ℃ to obtain the Francidine sulfate.
Wherein, the drug quality parameters of the Francidine sulfate are as follows: the titer is 650u/mg, and the content of neomycin C is 2.0%.
Example 2:
the embodiment of the invention provides a method for extracting franocidine sulfate from neomycin sulfate, which comprises the following steps:
s1, dissolving the concentrated neomycin sulfate raw powder with purified water with the weight 20-40 times that of the raw powder to obtain neomycin sulfate concentrated solution, adding a chromatographic resin with the model of HZ201, and adsorbing for 3-4 hours under the stirring condition, wherein the mass-to-volume ratio of the neomycin sulfate raw powder to the chromatographic resin is 1:5 until the chromatographic resin is saturated.
S2, washing the saturated chromatographic resin in the S1 by 0.3mol/L ammonia water, controlling the flow rate of the ammonia water to be 0.2 times of the volume of the chromatographic resin per hour (the flow rate of the ammonia water used in the S3 is the same), and washing the neomycin C and other impurities until the washing amount of the ammonia water is 3-4 times of the volume of the chromatographic resin.
S3, continuing to elute the neomycin sulfate B from the chromatography resin treated by the S2 by using 1.3mol/L ammonia water, starting to receive the eluent to an eluent receiving tank, and stopping eluting when the eluent is not turbid after being titrated by 5% phosphotungstic acid to obtain the eluent.
S4, concentrating the eluent by a thin film evaporator until the concentration of the eluent is 120000-180000u/ml, and obtaining the concentrated solution.
S5, adding 9mol/L sulfuric acid into the concentrated solution to adjust the pH value of the concentrated solution to 6, and carrying out the salt conversion operation.
S6, adding activated carbon into the concentrated solution of the reverse salt according to 0.05 kg/billion unit for decolorization, and performing filter pressing to obtain a decolorized solution.
S7, spray drying the decolored solution at the temperature of 135 ℃ to obtain the Francidine sulfate.
Wherein, the drug quality parameters of the Francidine sulfate are as follows: the potency is 652u/mg, the neomycin C content is 1.7%.
Example 3:
the embodiment of the invention provides a method for extracting franocidine sulfate from neomycin sulfate, which comprises the following steps:
s1, dissolving the concentrated neomycin sulfate raw powder with purified water with the weight 20-40 times that of the raw powder to obtain neomycin sulfate concentrated solution, adding a chromatography resin with the model number of LK20, and adsorbing for 3-4 hours under the stirring condition, wherein the mass-to-volume ratio of the neomycin sulfate raw powder to the chromatography resin is 1:5 until the chromatography resin is saturated.
S2, washing the saturated chromatographic resin in the S1 by 0.5mol/L ammonia water, controlling the flow rate of the ammonia water to be 0.1 time of the volume of the chromatographic resin per hour (the flow rate of the ammonia water used in the S3 is the same), and washing the neomycin C and other impurities until the washing amount of the ammonia water is 3-4 times of the volume of the chromatographic resin.
S3, continuing to elute the neomycin sulfate B from the chromatography resin treated by the S2 by using 1.5mol/L ammonia water, starting to receive the eluent to an eluent receiving tank, and stopping eluting when the eluent is not turbid after being titrated by 5% phosphotungstic acid to obtain the eluent.
S4, concentrating the eluent by a thin film evaporator until the concentration of the eluent is 120000-180000u/ml, and obtaining the concentrated solution.
S5, adding 9mol/L sulfuric acid into the concentrated solution to adjust the pH value of the concentrated solution to 6.5, and carrying out the salt conversion operation.
S6, adding activated carbon into the concentrated solution of the reverse salt according to 0.05 kg/billion unit for decolorization, and performing filter pressing to obtain a decolorized solution.
S7, spray drying the decolored solution at the temperature of 135 ℃ to obtain the Francidine sulfate.
Wherein, the drug quality parameters of the Francidine sulfate are as follows: the potency is 654u/mg, the content of neomycin C is 1.6%.
The chromatographic resin in S1 can be selected from HZ001, HZ201, LK20, LKC158HZ201, HZ3B and HPC3500 according to requirements.
In summary, the method for extracting franocidine sulfate from neomycin sulfate provided by the invention uses neomycin sulfate raw powder as a raw material, adopts chromatographic resin for selective adsorption, has a good separation effect, and is washed and analyzed by ammonia water with a concentration gradient, so as to reduce the dosage of ammonia water eluent.
Meanwhile, spray drying is adopted to replace crystallization operation, and crystallization operation is not carried out by using an organic solvent, so that the formed Franciseline sulfate finished product has no organic solvent residue, the finished product yield and the product quality are improved, the production cost is low, and meanwhile, no organic matter exists after waste liquid is discharged, and the environmental pollution caused by discharge can be reduced.
The above examples are only intended to illustrate the technical solution of the present invention, but not to limit it; although the present invention has been described in detail with reference to the foregoing embodiments, it will be understood by those of ordinary skill in the art that: the technical solutions described in the foregoing embodiments may still be modified, or some technical features may be equivalently replaced; and such modifications or substitutions do not depart from the spirit and scope of the corresponding technical solutions of the embodiments of the present invention.
Claims (9)
1. A method for extracting franocidine sulfate from neomycin sulfate is characterized by comprising the following steps:
s1, dissolving the concentrated neomycin sulfate raw powder with purified water with the weight 20-40 times that of the raw powder to obtain neomycin sulfate concentrated solution, adding chromatographic resin, and adsorbing for 3-4 hours under the stirring condition until the chromatographic resin is saturated;
s2, washing the saturated chromatographic resin in the S1 by 0.1-0.5mol/L ammonia water;
s3, eluting the chromatography resin treated by the S2 by using 1.1-1.5mol/L ammonia water to obtain eluent;
s4, concentrating the eluent by a thin film evaporator until the concentration of the eluent is 120000-180000u/ml, and obtaining a concentrated solution;
s5, adding sulfuric acid into the concentrated solution to carry out salt conversion operation;
s6, adding activated carbon into the salt-converted concentrated solution for decolorization and filter pressing to obtain a decolorized solution;
s7, spray drying the decolored solution at the temperature of 135 ℃ to obtain a finished product of the Francidine sulfate.
2. The method for extracting franocidine sulfate from neomycin sulfate as claimed in claim 1, wherein the mass-to-volume ratio of neomycin sulfate raw powder to the chromatography resin in S1 is 1: 5.
3. The method for extracting franocidine sulfate from neomycin sulfate as claimed in claim 2, wherein the chromatographic resin in S1 is selected from one of HZ001, HZ201, LK20, LKC158HZ201, HZ3B and HPC 3500.
4. The method for extracting franocidine sulfate from neomycin sulfate as in claim 1, wherein the ammonia wash flow rate in S2, S3 is 0.1-0.2 times the volume of the chromatography resin per hour.
5. The method for extracting franocidine sulfate from neomycin sulfate as in claim 4, wherein the amount of ammonia used in S2 is 3-4 times the volume of the chromatography resin.
6. The method for extracting franocidine sulfate from neomycin sulfate as in claim 1, wherein the elution of ammonia water in S3 is stopped until the eluate is not cloudy by titration with 5% phosphotungstic acid.
7. The process for extracting franocidine sulfate from neomycin sulfate as claimed in claim 1, wherein the concentration conditions in S4 are: the steam temperature is 40-50 ℃, and the vacuum degree is more than or equal to 0.085 MPa.
8. The method for extracting franocidine sulfate from neomycin sulfate as in claim 1, wherein the concentration of sulfuric acid in the operation of trans-salting in S5 is 6-9mol/L, and the pH of trans-salting is controlled to 6.0-7.0.
9. The method for extracting franocidine sulfate from neomycin sulfate as claimed in claim 1, wherein the finished product of franocidine sulfate in said S7 has the following pharmaceutical quality parameters: the potency is 650-654u/mg, the content of neomycin C is 1.6-2.0%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010165669.1A CN111333687A (en) | 2020-03-11 | 2020-03-11 | Method for extracting franocidine sulfate from neomycin sulfate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010165669.1A CN111333687A (en) | 2020-03-11 | 2020-03-11 | Method for extracting franocidine sulfate from neomycin sulfate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111333687A true CN111333687A (en) | 2020-06-26 |
Family
ID=71178216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010165669.1A Pending CN111333687A (en) | 2020-03-11 | 2020-03-11 | Method for extracting franocidine sulfate from neomycin sulfate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111333687A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112830948A (en) * | 2020-12-31 | 2021-05-25 | 浙江孚诺医药股份有限公司 | Method for extracting neomycin sulfate from neomycin fermentation liquor |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3147245A (en) * | 1961-02-03 | 1964-09-01 | Rohm & Haas | Pharmaceutical purification process |
| CN1059340A (en) * | 1991-07-11 | 1992-03-11 | 宜昌市光华发酵化工厂 | Extraction process of neomycin sulfate by use of static method |
| HU213477B (en) * | 1992-12-21 | 1997-06-30 | Biogal Gyogyszergyar | Process for preparing framycetin sulphate |
| CN101343295A (en) * | 2008-08-25 | 2009-01-14 | 石家庄华曙制药集团有限公司 | Method for extracting francisella native from bykomycin fermentation liquor |
| CN104610395A (en) * | 2015-01-19 | 2015-05-13 | 河北圣雪大成制药有限责任公司 | Method for extracting neomycin sulfate from neomycin sulfate fermentation broth |
| CN106317138A (en) * | 2016-08-25 | 2017-01-11 | 宁夏泰益欣生物科技有限公司 | Extraction method of neomycin sulfate |
| CN108976263A (en) * | 2018-09-13 | 2018-12-11 | 新宇药业股份有限公司 | A kind of sulfuric acid not draws the method for purification of rhzomorph |
-
2020
- 2020-03-11 CN CN202010165669.1A patent/CN111333687A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3147245A (en) * | 1961-02-03 | 1964-09-01 | Rohm & Haas | Pharmaceutical purification process |
| CN1059340A (en) * | 1991-07-11 | 1992-03-11 | 宜昌市光华发酵化工厂 | Extraction process of neomycin sulfate by use of static method |
| HU213477B (en) * | 1992-12-21 | 1997-06-30 | Biogal Gyogyszergyar | Process for preparing framycetin sulphate |
| CN101343295A (en) * | 2008-08-25 | 2009-01-14 | 石家庄华曙制药集团有限公司 | Method for extracting francisella native from bykomycin fermentation liquor |
| CN104610395A (en) * | 2015-01-19 | 2015-05-13 | 河北圣雪大成制药有限责任公司 | Method for extracting neomycin sulfate from neomycin sulfate fermentation broth |
| CN106317138A (en) * | 2016-08-25 | 2017-01-11 | 宁夏泰益欣生物科技有限公司 | Extraction method of neomycin sulfate |
| CN108976263A (en) * | 2018-09-13 | 2018-12-11 | 新宇药业股份有限公司 | A kind of sulfuric acid not draws the method for purification of rhzomorph |
Non-Patent Citations (3)
| Title |
|---|
| 俞文和 主编: "《新编抗生素工艺学》", 30 September 1996, 中国建材工业出版社 * |
| 夏守友: "硫酸弗拉菌素的制备及质量研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 邱小明: "新霉素发酵液提取工艺的优化研究", 《漳州职业技术学院学报》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112830948A (en) * | 2020-12-31 | 2021-05-25 | 浙江孚诺医药股份有限公司 | Method for extracting neomycin sulfate from neomycin fermentation liquor |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10131689B2 (en) | Separation and purification method for vancomycin hydrochloride of high purity | |
| CN102718843B (en) | Preparation method of single teicoplanin components | |
| CN106928323B (en) | Preparation method of high-purity oritavancin key intermediate A82846B | |
| CN105524128B (en) | A kind of continuous chromatography separating technology of Gentamicin C1a | |
| CN100447147C (en) | Aminoglycoside antibiotics enriching and purifying macroporous resin process | |
| CN1266159C (en) | Process for preparing gentamicin Cla | |
| CN101792822A (en) | Method for separating and purifying xylose and arabinose from hemicellulose acid hydrolysis liquid | |
| CN111333687A (en) | Method for extracting franocidine sulfate from neomycin sulfate | |
| CN102180922A (en) | Improved method for purifying erythromycin A | |
| CN101343295B (en) | Method for extracting francisella native from bykomycin fermentation liquor | |
| CN111056941B (en) | Method for preparing high-purity shikimic acid by utilizing ginkgo leaf extract chromatography waste liquid | |
| CN100463912C (en) | Membrane separating and purifying process for aminoglycoside antibiotics | |
| CN101805382A (en) | Separation and purification method of high-purity netilmicin | |
| CN107619421A (en) | The continuous chromatography isolation and purification method of lincomycin | |
| CN108570079B (en) | Method for purifying amikacin by weakly acidic cationic resin suction | |
| CN113045611B (en) | Preparation method of high-purity lincomycin hydrochloride | |
| CN111171096A (en) | Extraction method of pleocidin | |
| CN112409426B (en) | Preparation method of sisomicin sulfate | |
| CN114685618A (en) | Separation and purification method of monomers of each component of dalbavancin key intermediate A40926 | |
| CN112480214B (en) | Preparation method of dalbavancin key intermediate A40926 | |
| CN105061447B (en) | A kind of isolation and purification method of camptothecine | |
| CN111793103B (en) | Extraction process of apramycin sulfate | |
| Treiber et al. | Procedure for isolation of thienamycin from fermentation broths | |
| CN113698289B (en) | Method for preparing shikimic acid from ginkgo leaf extraction waste liquid | |
| CN111067965B (en) | Preparation method of bacopa monnieri saponin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200626 |